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Histone methyltransferase KMT2D harbors frequent loss-of-function somatic point mutations in several tu-
mor types, includingmelanoma. Here, we identify KMT2D as a potent tumor suppressor inmelanoma through
an in vivo epigenome-focused pooled RNAi screen and confirm the finding by using a genetically engineered
mouse model (GEMM) based on conditional and melanocyte-specific deletion of KMT2D. KMT2D-deficient
tumors show substantial reprogramming of key metabolic pathways, including glycolysis. KMT2D deficiency
aberrantly upregulates glycolysis enzymes, intermediate metabolites, and glucose consumption rates.
Mechanistically, KMT2D loss causes genome-wide reduction of H3K4me1-marked active enhancer chro-
matin states. Enhancer loss and subsequent repression of IGFBP5 activates IGF1R-AKT to increase glycol-
ysis in KMT2D-deficient cells. Pharmacological inhibition of glycolysis and insulin growth factor (IGF)
signaling reduce proliferation and tumorigenesis preferentially in KMT2D-deficient cells. We conclude that
KMT2D loss promotes tumorigenesis by facilitating an increased use of the glycolysis pathway for enhanced
biomass needs via enhancer reprogramming, thus presenting an opportunity for therapeutic intervention
through glycolysis or IGF pathway inhibitors.
INTRODUCTION
An important theme that has emerged from the cancer genome
sequencing studies in the past decade is genetic alterations in
epigenetic regulators implicating the epigenome as an important
player in cancer progression (Shen and Laird, 2013; Watson
et al., 2013). Loss-of-functionmissenseand nonsensepointmuta-
tions are observed to be highly prevalent across multiple tumor
types in two families of chromatin regulators: (1) Histone H3K4
methyltransferase members, including KMT2C and KMT2D
(Herz et al., 2012); and (2) SWI/SNF complex members, including
SMARCA4,ARID1A,andPBRM1 (Dawson,2017).Althoughrecent
studies have begun to shed light on the roles of these proteins in
cancer progression (Dhar et al., 2018; Koutsioumpa et al., 2019;
Lin-Shiao et al., 2018; Ortega-Molina et al., 2015; Zhang et al.,
2015), we still have limited knowledge of why mutations in these
proteins are selected over the course of tumor progression.
We focus our studies on metastatic melanoma that is an
aggressive cancer with a 5-year survival of less than 20% (Siegel
et al., 2018). In the past decade, the number of people affected by
the disease has increased tremendously (Siegel et al., 2018).
Although the landscape of available treatment options has
expanded for this disease in the form of immune checkpoint
blockade agents and targeted agents (such as BRAFi and
MEKi) (Luke et al., 2017), durable responses are observed in
only a subset of patients, leading several thousand people dying
of this disease every year. Hence, other treatment strategies
need to be further explored.
In cutaneous melanoma, mutations in epigenetic regulators,
including IDH1/2, EZH2, ARID1A/1B, ARID2, and SMARCA4,
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Figure 1. RNAi Screen Identifies Potential Melanoma Tumor Suppressor Genes
(A) Schematic of RNAi screen targeting epigenetic regulators to identify tumor suppressors in melanoma. HMEL-BRAFV600E cells were transfected in a pooled
fashion with 475 shRNAs targeting 95 epigenetic regulators (five shRNAs/gene) in 19 experimental pools (25 shRNAs targeting five genes per experimental pool).
Cells were orthotopically injected intradermally into the flanks of NCR-nude mice. Tumors that arose before the controls (shNT, shLuc, and shGFP) were
sequenced to identify the shRNA sequence.
(legend continued on next page)




have been observed at statistically significant frequencies (Hodis
et al., 2012; Krauthammer et al., 2012). However, we have a
limited understanding of how specificmutant epigenetic proteins
impact melanomagenesis. Functional studies have implicated
the involvement of other epigenetic factors, such as JARID1B
(Roesch et al., 2010), SETDB1 (Ceol et al., 2011), TET2 (Lian
et al., 2012), and histone variants (Kapoor et al., 2010; Varda-
basso et al., 2015), in melanoma progression. Systematic func-
tional approaches are needed to elucidate how misregulation
of epigenetic regulators impact chromatin states and down-
stream gene expression programs during various stages of
tumorigenesis. A detailedmechanistic understanding ofmelano-
magenesis and the role of epigenetic regulators will also inform
therapeutic strategies for patients whose tumors bear these mu-
tations. We isolated KMT2D as the top hit in an in vivo RNAi
screen focused on identification of epigenetic regulators that
play a tumor-suppressive function in melanoma. KMT2D is a his-
tone H3 lysine 4 (H3K4) methyltransferase that primarily per-
forms monomethylation, H3K4me1, which has been shown to
be a marker of enhancer elements (Herz et al., 2012; Lai et al.,
2017; Lee et al., 2013; Wang et al., 2016). KMT2D not only marks
nucleosome with H3K4me1 but also recruits CBP/p300 that in
turn acetylate these nucleosomes and hence lead to activation
of these enhancers (Lai et al., 2017; Lee et al., 2013; Wang
et al., 2016). Several studies have implicated enhancer aberra-
tions as a hallmark of multiple tumor types, including melanoma
(Akhtar-Zaidi et al., 2012; Chapuy et al., 2013; Gelato et al., 2018;
Herz et al., 2014; Hu et al., 2016; Lin et al., 2016; Lovén et al.,
2013; Mansour et al., 2014; Qian et al., 2014; Sur and Taipale,
2016; Verfaillie et al., 2015). However, most of them have
focused on aberrant enhancer activation, and little is known
about how enhancer inactivation, which may result from loss of
KMT2C/KMT2D function, influences tumor progression. We
establish that KMT2D-deficient tumors may exhibit reduced
enhancer activity that leads to the deregulation of energy meta-
bolism pathways, including glycolysis, thus providing a strategy
for targeting KMT2D mutant cancers.
RESULTS
Identification of Eight Potential Tumor Suppressors
including KMT2D through an RNAi Screen
We performed an RNAi screen (Figure 1A) to identify tumor-sup-
pressor epigenetic regulators in melanoma. We used a well-
characterized system of TERT-immortalized human primary
foreskin melanocytes that harbor stably integrated dominant
negative p53, CDK4R24C, and BRAFV600E (Garraway et al.,
2005; Fiziev et al., 2017) (passage, n < 15). They are referred
as HMEL-BRAFV600E. When injected in nude mice, HMEL-
BRAFV600E cells form visible tumors only after 22–24 weeks
and with low penetrance (10%–20%) (Figure 1B). In addition,
this line is poised to switch to the tumorigenic state upon addi-
tional cooperative driver alterations, such as PTEN loss (Fiziev
et al., 2017; Figure 1B). Hence, it is a relevant cell-based system
for discovering tumor-promoting events, as it provides a minimal
yet sensitized tumorigenic background to identify moderate-to-
potent tumor suppressors. We had previously used this system
for the discovery of pro-tumorigenic epigenomic changes inmel-
anoma (Fiziev et al., 2017).
In the current study, we constructed a short hairpin RNA
(shRNA) expression vector library that included 475 shRNAs tar-
geting 95 proteins known to regulate epigenetic processes,
including chromatin modification and nucleosome remodeling
(Table S1). The HMEL-BRAFV600E cells were transfected with
23 pools of shRNAs individually. Hereafter, ‘‘pool’’ refers to sta-
bly transfected HMEL-BRAFv600E cells. Of these pools, 19 exper-
imental pools contained 25 shRNAs each (five shRNAs each for
five genes selected randomly). The three negative pools con-
tained one negative-control shRNA each (shGFP, shLacZ, and
shNT [non-targeting]) and final pool harbored PTEN shRNA
(shPTEN) as a positive control (Figure 1B). Briefly, one million
cells were orthotopically injected intradermally in nude mice
(10 sites) that were monitored for visible tumor formation over
the subsequent 25 weeks (Figures 1B and S1A). Mice injected
with cells from eight of the 19 pools and the positive control
(shPTEN) displayed a significant acceleration of tumor formation
compared with the negative controls. The first occurrence of tu-
mor formation was at 5 weeks, whereas tumor formation did not
occur until 22 weeks in the negative-control mice and multiple
pools (Figures 1B, 1C, and S1A).
We next identified the shRNAs enriched in DNA of tumors har-
vested from the mice exhibiting significantly accelerated tumor
formation by performing Sanger sequencing of the pLKO ampli-
fied region containing shRNA (list of genes in Figure 1C). We
identified eight unique shRNAs each from eight pools that signif-
icantly accelerated tumor formation. To validate the results of the
screen, we knocked down each of the eight candidate genes
individually by using at least two independently validated
shRNAs in HMEL-BRAFV600E and widely used WM115
(BRAFV600E mutant) melanoma cells (Figures S1B–S1I) and
tested tumor formation efficiency (Figures 1D–1K and S1J–
S1P). All eight genes (KMT2D, KDM1A, APOBEC2, HDAC6,
KMT2F, SETD4, KAT4, and KDM5B) were validated as tumor
suppressor candidates, as knockdown of these genes in both
HMEL-BRAFV600E and WM115 cells resulted in accelerated
tumor formation (p < 0.05) (Figures 1D–1K and S1J–S1P). In
(B) Kaplan-Meier curve showing tumor-free survival of mouse cohorts orthotopically injected with one million HMEL-BRAFv600E cells transfected with pooled
shRNAs from primary screen. Nineteen experimental pools (P1–P19), three negative control pools (shLuc, shGFP, and shNT), and one positive control (shPTEN)
were injected in 10 mice each, and tumor formation was monitored over 25 weeks. Mantel-Cox test, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 10 per pool. Only
pools that show significant acceleration are shown here. For data on non-significant pools, please see Figure S1A.
(C) List of genes identified from their pools, the week of first appearance of tumor in the pool, and the percentage of mice in respective cohort demonstrating
accelerated tumorigenesis over control mice (penetrance).
(D–K) Kaplan-Meier curves showing tumor-free survival of mouse cohorts orthotopically injected with HMEL-BRAFV600E cells stably expressing shRNAs against
KMT2D (D), KDM1A (E), APOBEC2 (F), HDAC6 (G), KMT2F (H), SETD4 (I), KAT4 (J), and KDM5B (K). Mantel-Cox test, *p < 0.05, **p < 0.01, and ***p < 0.001; n = 10
per arm.











Figure 2. KMT2D Functions as a Tumor Suppressor in BRAFV600E Mutant Melanomas
(A and D) Kaplan-Meier curve showing tumor-free survival of mouse cohorts orthotopically injected with WM115 (A) and WM266-4 (D) cells stably expressing
shRNAs against KMT2D. Mantel-Cox test, *p < 0.05; n = 10 per arm.
(B) Schematic of KMT2D protein showing missense mutations seen across all melanoma studies deposited in the cBio portal. Green-filled circles indicate
missense mutations, black-filled circles indicate truncating mutations, and red circles indicate functional mutations occurring after amino acid residue 4700.
Colored boxes within the KMT2D schematic show different protein domains.
(C) Stacked bar chart showing percentage of nevi (n = 18), primary melanoma (n = 62), andmetastatic melanoma (n = 22, labeled ‘‘Met’’) samples with the various
intensity (of KMT2D expression) categories (0, 0.5, 1, 2, and 3, as shown in the legend). The p value for the difference in average intensity of KMT2D expression
between primary and nevi was <0.05. Similarly, the p value for the difference in average intensity of KMT2D expression between primary and metastatic mel-
anoma was <0.05.
(E) Kaplan-Meier curve of auricular tumor-free survival in KMT2D WT (KMT2D+/+, blue, n = 40), KMT2D heterozygous (KMT2DL/+, green, n = 12), and KMT2D
mutant (KMT2DL/L, red, n = 19) mice in an iBIP (Tyr-CreERT2, Rosa26-rtta, TetO-BRAFV600E, PTENL/L, INK/ARFL/L) background that were treated with doxycycline
(dox) (2 mg/ml, ad libitum) and 4-OHT (1 mM, topical). The x axis refers to days after 4-OHT application. Mantel-Cox test, *p < 0.05, **p < 0.01, and ***p < 0.001.
(legend continued on next page)




addition, knockdown of a subset of these genes in HMEL-
BRAFV600E cells also promoted invasion in vitro in a Boyden
chamber assay (Figure S1Q). KMT2D was the most potent hit,
asmice injected with cells with stable KMT2D knockdown devel-
oped tumor appearance at the earliest interval and with the high-
est penetrance compared with negative controls (Figures 1C,
1D, and 2A). Among the rest, KDM5B has been previously impli-
cated in melanoma for which it is believed to control the mainte-
nance of slow cycling melanoma cells and displays complex
phenotypes during tumor progression (Roesch et al., 2010).
Genetically Engineered Mouse Model (GEMM) Confirms
KMT2D Is a Potent Tumor Suppressor in Melanoma
We searched published melanoma genomic studies to identify
patients whose tumors harbor genetic aberrations in the poten-
tial tumor suppressor genes discovered through the screen. We
observed that 15% of melanoma cases identified harbored
missense mutations in KMT2D, whereas 5%–8% of patients
harbored missense mutations in KAT4 (Figures 2B and S2A)
(Cancer Genome Atlas Network, 2015b). As KMT2D mutations
are prevalent (Cancer Genome Atlas Network, 2015a; da Silva
Almeida et al., 2015; Gao et al., 2014; Grasso et al., 2012; Jones
et al., 2012; Juhlin et al., 2015; Kandoth et al., 2013; Lawrence
et al., 2014; Lin et al., 2014; Lohr et al., 2012; Morin et al.,
2011; Parsons et al., 2011; Pasqualucci et al., 2011; Pugh
et al., 2012; Rao and Dou, 2015; Sausen et al., 2015; Song
et al., 2014) and this gene is increasingly reported to be a poten-
tial tumor suppressor across other tumor types (Dhar et al., 2018;
Koutsioumpa et al., 2019; Lin-Shiao et al., 2018; Ortega-Molina
et al., 2015; Rao and Dou, 2015; Zhang et al., 2015), we next
sought to deeply characterize the mechanism of action of
KMT2D in melanoma, particularly as the strongest phenotype
(fastest tumor growth) in RNAi screen was seen with the
KMT2D loss. A subset of the missense mutations in KMT2D
were truncating or frameshift insertions/deletions (4.4%) that
likely abrogate histone methyltransferase activity (Figure 2B). In
addition, 10%of all missensemutations occurred distal to amino
acid residue 4700 that were shown to disrupt histone methyl-
transferase activity in a previous study (Zhang et al., 2015).
Together, we categorize these set of mutations—truncating,
frameshift, and post4700aa—as ‘‘functional’’ driver mutations
for KMT2D. Although we make use of this stringent criteria as
a deterministic measure for KMT2D-deficient tumors so that
we can delineate its mechanism of action, it is not a reflection
of all KMT2D somatic variants thatmay produce a non-functional
KMT2D protein.
First, we checked if, in addition to mutations, KMT2D mRNA
and protein levels were also altered in human melanoma. Stain-
ing of a tissue microarray (TMA) harboring 100 cases of nevi,
primary melanomas, and metastatic melanomas showed a sig-
nificant progressive loss of KMT2D protein levels in primary
andmetastatic melanomas (Figures 2C and S2B). A similar trend
was also observed in mRNA expression of KMT2D, as identified
by the assessment of publicly available melanoma progression
transcriptomic datasets (Talantov et al., 2005; Xu et al., 2008;
Figure S2C) suggesting KMT2D regulation at both the level of
gene expression and somatic mutations.
Functionally, knockdown of KMT2D by two different shRNAs
led to increased tumor burden in two clonal variants of HMEL-
BRAFV600E, namely, WM115 and WM266-4 cells (Figures 1D,
2A, 2D, and S2D–S2H). In addition, an increase in soft agar col-
ony formation (Figure S2I) and invasion (Figure S2J) was
observed in vitro. To further verify the role of KMT2D in mela-
noma in a specific genetic context, we used a conditional mouse
model of KMT2D that harbors Lox sites flanking exons 16–20,
thereby leading to deletion of this gene in a tissue-specific
manner (Dhar et al., 2018). Melanocyte-specific deletion with
Tyr-CreERT2 did not result in the formation of melanomas (data
not shown), and thus, these mice were crossed with a previously
published doxycycline- and a tamoxifen-inducible mouse model
of BRAFV600E melanoma (iBIP = Tyr-CreERT2, Rosa26-rtta, TetO-
BRAFV600E, PTENL/L, INK/ARFL/L). Tamoxifen application on the
ears of KMT2D mutant iBIP mice resulted in a drastic accelera-
tion of tumorigenesis compared with KMT2D wild-type (WT)
iBIP mice (Figures 2E and 2F). Intriguingly, the heterozygous
mice also showed significant acceleration of auricular tumor
burden (Figures 2E and 2F). Furthermore, increased proliferation
and melanocyte origin was confirmed by immunohistochemical
analysis (IHC) for Ki-67 and tyrosinase, respectively (Figures
2G and S2K).
Next, we derived cell lines from the tumors of two KMT2D WT
(iBIP-KMT2D+/+) and two mutant (Mut, iBIP-KMT2DL/L) models
(Figure 2H) and confirmed the genotype of all alleles. The two
KMT2D WT iBIP cell lines were labeled as WT-m1 and WT-m2
for WT mouse 1 and 2; and the two KMT2D mutant cell lines
were labeled as Mut-m1 and Mut-m2 for mutant mouse 1
and 2 (Figure 2H). These lines were verified for the loss of
KMT2D mRNA by qPCR (Figure S2L) and protein by immunoflu-
orescence (Figure S2M). The phenotypes observed in KMT2D
mutant lines were dependent on the loss of this gene, as overex-
pression of full-length KMT2D (Figures 2I and S2M) reduced tu-
mor burden in vivo (Figure 2J) in immunodeficient nude mice. To
(F) Tumor burden of KMT2D WT (KMT2D+/+, blue, n = 40), KMT2D heterozygous (KMT2DL/+, green, n = 12), and KMT2D mutant (KMT2DL/L, red, n = 19) mice in
iBIP background at 89 days after 4-OHT application.
(G) Images of Ki-67-stained (standard immunohistochemistry) (403) melanoma tumors from iBIP;KMT2D+/+ and iBIP;KMT2DL/L mice. Right panel shows per-
centage of Ki-67-stained cells across five different fields of 100 cells each. Scale bars represent 20 mm.
(H) Table showing the humanmelanoma lines and iBIP;KMT2D-mouse-model-derived cells that were used in the functional studies through the rest of the figures.
(I) Bar graph showing KMT2D expression levels (n = 3) in WT-m1, Mut-m2, and Mut-m2 + hKMT2D lines (left panel) or in WT-h1, Mut-h1, and Mut-h1 + hKMT2D
lines (right panel). The y axis represents fold change of the gene expression compared to 28S and normalized to Mut-m2 or Mut-h1 lines. *** p < 0.001 (unpaired t
test comparison between the indicated groups) See Figure S2I for protein levels.
(J) Graph showing tumor volume of nude mice (n = 10 per group) injected with KMT2D mutant murine (Mut-m2) or human (Mut-h1) cells harboring an inducible
KMT2D expression vector that leads to KMT2D overexpression upon application of dox. p values represent t test comparison between the indicated groups on
the last time point. In this graph, **p < 0.001 and ***p < 0.000001.
In (G) and (I), data are presented as the mean ± SEM (error bars) of at least three independent experiments or biological replicates.
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assess relevance in humans, we performed all of the follow-up
experiments in two KMT2D WT human melanoma lines (A375
and RPMI-7951 that are referred to hereafter as WT-h1 and
WT-h2) and two KMT2D mutant human melanoma lines
(SKMEL-24 and WM278 that are referred to hereafter as Mut-
h1 and Mut-h2) (Figures 2H and S2M). Mut-h1 and Mut-h2 har-
bor truncatingmutations at Q2800 andQ2062, respectively (Iorio
et al., 2016). Similar to the murine system, overexpression of
hKMT2D rescued the tumorigenesis phenotype in the human
cell lines (Figures 2I, 2J, and S2M).
Hyperactive Glycolysis in KMT2D Mutant Tumors Is a
Targetable Pathway
To determine the molecular phenotype conferred by KMT2D
loss, we performed an RNA sequencing (RNA-seq)-based tran-
scriptome profiling experiment in the KMT2D WT and mutant
murine melanoma lines. We identified 1,761 genes that were
uniquely overexpressed in the KMT2D mutant compared with
WT conditions (false discovery rate [FDR] < 0.05, fold change
[FC] > 2, n = 3) and 1,443 that were repressed. Genes overex-
pressed in KMT2D mutant cells were enriched for pathways
related to immune response, cell adhesion, and epithelial-to-
mesenchymal transition, as well as various metabolic pathways,
including the ‘‘hexose metabolic pathway’’ or glycolysis (Figures
3A, 3B, S3A, and S3B; Table S2). Similar pathways, including
glycolysis, were also found to be upregulated in KMT2D mutant
human melanomas upon analyses of melanoma tumors from a
published TCGA study (Figure 3C; Table S2). They included
many glycolysis enzymes, including PGAM1, PGK1, ENO1,
HK2, GAPDH, TPI1, and LDHA, as well as its upstream regula-
tors (Figure S3C; Table S2). A survey of pan-cancer TCGA data
suggested that energy metabolism pathways, including glycol-
ysis, were activated across 6 other tumor types (BLCA [urothelial
bladder carcinoma], CESC [cervical squamous cell carcinoma],
endocervical adenocarcinoma, HNSC [head and neck squa-
mous cell carcinoma], LUSC [lung squamous cell carcinoma],
UCEC [uterine corpus endometrial carcinoma], and STAD
[stomach adenocarcinoma]) that harbor functional KMT2D driver
mutations (Figures 3D and S3D; Table S2). We observed drastic
upregulation of 10 out of 12 glycolysis pathway enzyme genes
(GLUT1, HK1, GPI1, PFKA, ALDOC, TPI1, GAPDH, PGK1,
PGAM1, and ENO1) by qPCR in KMT2D mutant lines compared
with WT lines in both human and murine models (Figures 3E and
3F). Similarly, the rescue of mutant lines with full-length WT
KMT2D reduced their expression (Figure 3G). Higher expression
of ENO1, PGK1, and PGAM1 was confirmed in KMT2D mutant
iBIP melanoma tumors by IHC (Figure 3H). Quantitation of
glucose uptake and lactate production confirmed upregulation
of glycolysis in the KMT2D mutant lines (Figures 3I and 3J) that
was reduced upon KMT2D overexpression (Figure 3K). In addi-
tion, mass-spectrometry-based quantitative measurement of
glycolysis intermediate metabolites showed higher levels of
fructose-1,6-biphosphate, D-glyceraldehyde-3-phosphate, di-
hydroxy-acetone-phosphate, 1,3-diphosphateglycerate, and
pyruvate in two KMT2D mutant murine lines than those of two
WT lines (Figure 3L). We also noted a modest increase in some
TCAmetabolites, amino acids, and sugars, whereas the Pentose
Phosphate pathway metabolites either did not change or
showed a modest decrease in KMT2D mutant cells compared
with WT cells (Figures S3E–S3H). Consistent with this higher
glycolysis rate in KMT2D mutants, they grew poorly in low
glucose media compared to high glucose media, which likely re-
sulted from rapid exhaustion of glucose in the media (Figures
S4A and S4B). A trivial explanation for the increase in glycolysis
in KMT2Dmutant cells would be the higher proliferative potential
of these cells than that of WT cells. However, contradictory to
this hypothesis, we observe that KMT2D mutant cells proliferate
more slowly than WT cells in vitro (Figures S4A and S4B) despite
increased tumorigenesis in vivo. Similarly, re-expression of
KMT2D in human and mouse KMT2D mutant cells modestly
increased their proliferation (Figure S4C). Together, these data
provide the evidence of activation of glycolysis in KMT2Dmutant
Figure 3. KMT2D Mutated Tissues Exhibit Aberrant Activation of Glycolysis
(A) Top five Gene Ontology (GO) terms for upregulated genes (FDR < 0.05, FC > 2) between KMT2D mutant murine cells and KMT2D WT cells by total RNA-seq
analysis.
(B) Enrichment plot for HALLMARK glycolysis pathway in all differentially expressed genes (FDR < 0.05, FC > 2) between KMT2Dmutant murine cells and KMT2D
WT cells by total RNA-seq analysis. Each black bar represents a gene in the pathway.
(C) GSEA plot of the HALLMARK glycolysis pathway in differentially expressed genes between human primary melanomas with low versus high KMT2D
expression (n = 10 for each group) from the TCGA-SKCM cohort. Each black bar represents a gene in the pathway.
(D) GSEA of different MSigDB energy metabolism pathways in differentially expressed genes between KMT2D mutant (carrying truncation, frameshift and
post4700aa missense) and WT human tumors from six TCGA tumor groups where KMT2D mutant tumors are n > 10.
(E–G) Bar graph showing the relative expression pattern (n = 3 for each sample) of 12 glycolysis enzyme genes (compared to 28S) in KMT2D mutant and WT
murine (E) and human (F) cells (details of the system in Figure 2H) as well as in Mut-m1 and Mut-h1 cells with dox-inducible rescue of full-length WT KMT2D
expression (G). *p < 0.05, **p < 0.001, ***p < 0.0001. Unpaired t test p values were calculated for each mutant sample versus both WT samples separately, and a
higher p value is shown in the figure when both were significant.
(H) Immunohistochemistry images demonstrating expression of ENO1, PGK1, and PGAM1, encoded by three glycolysis genes, in iBIP;KMT2D+/+ and
iBIP;KMT2DL/L melanoma tumors. Scale bars represent 20 mm.
(I–K) Graph showing measurement of glucose uptake and lactate production (n = 3 for each sample) in KMT2D mutant and WT murine (I) and human (J) cells
(details of the system in Figure 2H) as well as in the KMT2D mutant mouse Mut-m1 and human Mut-h1 cells with dox-inducible rescue of full-length WT KMT2D
expression (K).
(L) Bar graph showing relative levels (n = 3 for each sample) of variousmetabolite intermediates produced during the glycolysis pathway, asmeasured by selected
reaction monitoring tandem mass spectrometry. *p < 0.05, **p < 0.01, ***p < 0.001.
(M) Schematic of the glycolysis pathway showing aberrantly activated glycolysis enzymes (in red) and metabolites (in blue) of KMT2D mutant compared to WT
conditions.
In (E)–(G) and (I)–(L), data are presented as the mean ± SEM (error bars) of at least three independent experiments or biological replicates.












Figure 4. Inhibition of Glycolysis Preferentially Impacts KMT2D Mutant Cells
(A–D) Growth curves for KMT2Dmutant andWTmurine (A andC) and human (B and D)melanoma cells treated with various concentrations of 2-deoxy-D-glucose
(A and B) or pomhex (C and D). Relative confluence at 96 h posttreatment are plotted, and IC50 values are shown in the accompanying table.
(legend continued on next page)




melanomas (Figure 3M) that likely helps meet the increased
biomass and energy requirements for increased tumorigenesis.
Next, we tested whether the aberrantly activated glycolysis
pathway contributed to the increased tumorigenic potential of
KMT2D mutant melanomas. Inhibition of the glycolysis pathway
using three different inhibitors—2-DG (glucose competitor),
pomhex (an ENO1 inhibitor; Lin et al., 2018), and lonidamine
(Hexokinase inhibitor—selectively reduced the proliferation of
KMT2D mutant melanoma cells compared with that of KMT2D
WT melanoma cells in both murine as well as human systems
(Figures 4A–4D, S4D, and S4E; Table S3). This effect was
more pronounced in low glucose conditions than in high glucose
media (Figures S4F and S4G). This preferential effect of 2-DG on
KMT2D mutant murine and human cell lines was rescued with
the expression of WT KMT2D (Figures 4E and 4F). Consistent
with the in vitro data, tumors formed by xenotransplantation of
KMT2D mutant lines were more sensitive to 2-DG treatment in
nude mice (Figures 4G and 4H). Importantly, we did not observe
preferential growth inhibition of KMT2D mutant murine cells
comparwith WT cells by a OxPhos inhibitor, IACS-10759 (Fig-
ure S4H). Together, these data suggest that upregulated glycol-
ysis is an important contributor to enhanced tumorigenesis in
KMT2D mutant melanomas and suggest a potential therapeutic
strategy in this genetic context.
H3K4me1-Marked Enhancer Reprogramming Occurs in
KMT2D Mutant Melanoma
We examined total and genome-wide levels of H3K4 marks, as
KMT2D is known to harbor histone methyltransferase activity to-
ward multiple H3K4 methylation states and impacts H3K27ac
patterns (Dhar et al., 2018; Dorighi et al., 2017; Lee et al.,
2007, 2013; Wang et al., 2016). KMT2D mutant murine cells
harbored lower levels of total H3K4me1 and H3K27ac marks
than those inWT cells (Figures 5A andS5A), andH3K4me1 levels
were elevated upon KMT2D re-expression (Figure S5B). Immu-
nohistochemistry staining of a TCGAmelanoma tumor TMA sug-
gests that KMT2D expression levels correlate with those of
H3K4me1, H3K27ac, and H3K4me3 (Figures 5B and S5C). We
also observed a significant loss of H3K4me1 but not H3K27Ac
in KMT2D mutant Cancer Cell Line Encyclopedia (CCLE) pan-
cancer cell lines (Figures 5C and S5D). Consistently, mass-spec-
trometry-based quantitation of histone modifications in KMT2D
mutant murine cells showed a modest loss of H3K4me1,
H3K27ac, and H3K4me3 (Figure S5E). Next, we determined
chromatin states in murine melanoma KMT2D mutant and WT
tumors using chromatin immunoprecipitation sequencing
(ChIP-seq) for the histone modifications H3K4Me1 (enhancers),
H3K4Me3 (promoters), H3K27Ac (active), H3K79Me2 (transcrip-
tion), and H3K27Me3 (polycomb-repressed) (Maunakea et al.,
2010), in line with studies from the NIH Roadmap project (Kun-
daje et al., 2015). Chromatin state calls using a 10-state
ChromHMM model representing various epigenomic states,
including promoters (states 3 and 4), enhancers (states 2, 5,
and 6), polycomb repressed (state 9), transcribed (state 1), and
unmarked (states 8 and 10) (Figure 5D). Chromatin state transi-
tion between KMT2D mutant and WT cells identified state 6
(active enhancer, H3K4me1 high) to 10 (low) as the most prom-
inent transition that was associated with a loss of H3K4me1- and
H3K27ac-based enhancers (Figure 5E). The other two prominent
changes (i.e., state 2 [transcribed enhancer] to 1 [transcribed],
and state 3 [transcribed 50 and 30 promoter] to 2 [transcribed
enhancer]) were associated with the loss of H3K4me1 and
H3K4me3, respectively (Figure 5E). An examination of average
intensities of individual H3K4me1 and H3K27ac marks across
the genome showed a significant reduction of H3K4me1 and lit-
tle/no change in H3K27ac (Figures 5F and 5G). Similarly, we
observed changes in H3K4me1-based superenhancer regions
but not those called by the H3K27ac signal (Figures S5F and
S5G). Importantly, we also noticed a pronounced increase in
the average intensities of H3K27me3 peaks in KMT2D mutants
compared with WT samples on enhancer loci that lose the
H3K4me1 mark that could imply a transcriptional repression of
a subset of genes (Figure 5H). H3K27me3 peaks also showed
modest genome-wide enrichment (Figure S5H) that could be
due to loss of function of H3K27me3-specific demethylase,
KDM6A, which is known to be an obligate partner of KMT2D
(Lee et al., 2007). On the contrary, we did not notice much
change in H3K79me2 and H3K4me3 enrichment between
KMT2D WT and mutant tumors (Figures S5I and S5J). We
compared the overlapping H3K27ac and H3K4me1 peaks be-
tween KMT2D mutant and WT cells to identify 7,555 active
enhancer peaks that were lost in mutant cells (Figure 5H). These
lost active enhancer peaks were associated with important mel-
anoma regulatory genes in immune pathways, apoptosis
signaling pathway, and p53 pathway by glucose deprivation
(Figure S5K). These data suggest that KMT2D loss results in sig-
nificant reprogramming of the enhancer landscape inmelanoma.
Upregulated Insulin Growth Factor (IGF) Signaling
Regulates Glycolysis in KMT2D Mutants
To understand how enhancer loss may lead to observed meta-
bolic reprogramming, we overlapped changes in gene expression
betweenKMT2DWTandmutant-murine-tumor-derived lineswith
the changes in active enhancer patterns. Of the 7,555 active
enhancer loci that display a loss of intensity in KMT2D mutant tu-
mors compared with WT, 1,165 were located nearby (±200 Kb)
genes with decreased expression (Figure 6A). We found a signifi-
cant association between the loss of expression and loss of
H3K4me1 patterns in nearby loci (Figure S6A). These genes
wereenriched for those involved invariousphosphorylation-medi-
ated cell signaling events and are bona fideor putative tumor sup-
pressors (Figures S6B and S6C). Of these, we focused on the IGF
signaling pathway that is known to play major roles in regulating
metabolic pathways (such as glycolysis) by activation of AKT
(E and F) Growth curves for KMT2D mutant mouse Mut-m2 (E) and human Mut-h1 (F) melanoma cells that express inducible KMT2D (with 10 mg/ml doxycycline
application). Relative confluence at 96-h posttreatment are plotted, and IC50 values are shown in the accompanying table.
(G andH) Line plot showing average tumor volumes formice (n = 10 per group) injectedwith KMT2Dmutant andWTmurine (G) and human (H) melanoma cells and
treated with 2-DG (500mg/kg) every other day. p values represent t test comparison between the indicated groups on the last time point. In this graph, **p < 0.001
and ***p < 0.000001.
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(Wang et al., 2015; Figures S6B and S6C). Indeed, we observed
higher levels of pAKT (S473) and pIGF1R (Y1198) in KMT2D
mutant murine and human lines (Figure 6B) as well as KMT2D
mutant iBIP tumors (Figure 6C), suggesting aberrant activation
of the IGF-AKT-glycolysis pathway. Examination of Reverse Pro-
tein Phase Array (RPPA) data fromCCLE database (Li et al., 2017)
across all cancer types showed that KMT2D mutant cell lines
(harboring functional driver mutations) showed higher levels of
pS473 and pT308 forms of AKT compared to KMT2D WT (and
high expressing) lines (Figure 6D). However, in contrast to obser-
vations in pancreatic cancer (Koutsioumpa et al., 2019), we
observed reduced levels of the phosphorylated form of mTOR
(mammalian target of rapamycin) in KMT2D mutant versus WT
cells in theCCLEdatabaseRPPAdata (FigureS6D). The functional
significance of activation of IGF1R signaling was further tested by
the treatment of cells with an IGF-1R inhibitor (linsitinib), which
reduced the expression of glycolysis genes in KMT2D mutant
murine and human cell lines (Figures 6E and 6F). Importantly,
treatment of KMT2D mutant murine and human cell lines with lin-
sitinib preferentially reduced the proliferation of KMT2D mutant
cell lines both in vitro (Figure 6G) and in vivo (Figures 6H and 6I).
This findingwas recapitulated in the analysis of all cancer cell lines
(fromSangerCell Linedatabase) forwhich linsitinibsensitivitydata
wereavailable.CellsharboringKMT2D functional drivermutations
displayed significantly lower IC50 (half maximal inhibitory concen-
tration) values for linsitinib treatment than for cells that harbor high
levels of KMT2D (and have WT protein) (Figure 6J). Finally, linsiti-
nib-treated tumors showed a drastic reduction in the expression
of glycolysis genes, proliferation marker Ki-67, and pAKT levels
(Figure S6E). These data establish activation of the IGF1R-AKT-
glycolysis axis in KMT2D-deficient cancer cells.
Loss of a Distal Enhancer of IGFBP5 in KMT2D Mutants
Regulates IGF Signaling and Expression of Glycolysis
Enzyme Genes
Wenext searched for putative regulators of the IGF signaling that
lose active enhancers and gene expression in KMT2D mutants
specifically to identify those that may be responsible for the
metabolic reprogramming phenotypes observed in KMT2D-defi-
cient tumors. We focused on IGFBP5 as it is a known negative
regulator of IGF1R signaling and acts as a tumor suppressor in
melanoma by regulation of AKT and IGF1R signaling (Wang
et al., 2015). We found the loss of H3K4me1 signals on proximal
and distal enhancers were associated with IGFBP5 in KMT2D
mutant tissues (Figure 7A), whereas other IGFBPs did not
show a significant change (Figure S7A). Examination of Hi-C-
based higher order chromatin interaction data showed that
IGFBP5 may be located in a TAD (Tandem Adjacent Domain),
thus promoting the interaction between this distal enhancer
and the IGFBP5 gene (Figure 7B). Consistently, IGFBP5 expres-
sion was also lost in KMT2D mutant murine and human cell lines
(Figure 7C), whereas several other IGFBPs showed inconsistent
patterns (Figure S7B). Consistently, IGFBP5 expression was
significantly reduced in KMT2D mutant human and murine mel-
anoma tumors (Figures 7D, S7C, and S7D). Consistently, we also
noted a positive correlation between IGFBP5 expression and
KMT2D expression in the metastatic tumors in the TCGA mela-
noma study (Figure S7E; Cancer Genome Atlas Network,
2015b). Our recent study in lung cancer identified KMT2D-medi-
ated regulation of Per2 expression as the central node in the
regulation of glycolysis enzymes (Alam et al., 2020). However,
we did not find any difference in Per2 expression in KMT2D
WT versus mutant murine or human melanoma tumors (Figures
S7C and S7D). We also did not observe any change in TSC1
expression in KMT2D mutant versus WT cell lines (Figure S7C).
Knockdownof IGFBP5 in themurine cell line using two shRNAs
(30%–50%) led to an increasedexpression of glycolysis enzymes
(Figure S7F). Importantly, epistasis experiments revealed that
IGFBP5 overexpression in murine melanoma cells decreased
levels of IGF1R and AKT phosphorylation (Figure 7E) as well as
glycolysis genes (Figures 7F and 7G) in KMT2D mutant murine
and human cells compared with their WT counterparts. Taken
together, the data presented in thismanuscript establish amodel
of KMT2D function in cancer for which KMT2D acts as a tumor
suppressor by enhancer reprogramming on tumor suppressor
genes, such as IGFBP5, that regulate key pathways, such as
IGF1R signaling, leading to metabolic rewiring (Figure 7H).
DISCUSSION
Through an unbiased RNAi screen in vivo, we identified and vali-
dated eight epigenetic modifiers (KMT2D, KDM1A, APOBEC2,
Figure 5. KMT2D Loss Is Associated with Loss of H3K4me1-Marked Enhancers
(A) Western blot showing total H3K4me1, H3K27ac, H3K4me3, and H3 in KMT2D mutant (Mut-m1, Mut-m2, Mut-h1, and Mut-h2) and WT (WT-m1, WT-m2, WT-
h1, and WT-h2) murine (right) and human (left) melanoma cells.
(B) Bar chart showing immunohistochemistry-based staining of melanoma tumors (MDACC TCGA samples) in a tissue microarray for KMT2D, H3K4me1 (left
panel), and H3K27ac (right panel). KMT2D intensity was grouped into low (score of 1 or 1.5, n = 10), mid (score of 2, n = 57), and high (score of 3, n = 33) groups,
and percent positive cores with similar intensity groups for H3K4me1 or H3K27ac were plotted on y axis.
(C) Boxplot showing relative levels of H3K4me1 in KMT2Dmutant (n = 126) or WT (n = 293) cells using the mass spectrometry data from the CCLE database. The
bottom and the top rectangles indicate the first quartile (Q1) and third quartile (Q3), respectively. The horizontal lines in the middle signify the median (Q2), and the
vertical lines that extend from the top and the bottom of the plot indicate the maximum and minimum values, respectively.
(D) Emission probabilities of the 10-state ChromHMM model on the basis of ChIP-seq profiles of five histone marks (shown in x axis). Each row represents one
chromatin state, and each column corresponds to one chromatin mark. The intensity of the color in each cell reflects the frequency of occurrence of that mark in
the corresponding chromatin state on the scale from 0 (white) to 1 (red). States were manually grouped and given candidate annotations.
(E) Heatmap showing the fold enrichment of chromatin state transitions between KMT2D mutant (KMT2DL/L) and WT (KMT2D+/+) samples for the 10-state model
defined by the ChromHMM. Color intensities represent the relative fold enrichment. Blue box and arrow point to active enhancer state switch.
(F and G) Heatmaps (left panels) and average intensity curves (right panels) of ChIP-seq reads (RPKM, reads per kilobase of transcript, per million mapped reads)
for H3K4me1 (F) and H3K27ac (G) at typical enhancer regions. Enhancers are shown in a 10-kb window centered on themiddle of the enhancer in iBIP;KMT2D+/+
and iBIP;KMT2DL/L melanoma tumors.
(H) Venn diagram showing unique or shared H3K4me1 andH3K27Ac co-enriched active enhancers sites in iBIP;KMT2D+/+ and iBIP;KMT2DL/Lmelanoma tumors.












Figure 6. Aberrant Activation of IGF and AKT Signaling in KMT2D Mutants Confers Sensitivity to IGFR Inhibitor
(A) Venn diagram showing the overlap between differentially expressed genes and lost active enhancer loci in KMT2Dmutant (Mut-m2)melanoma cells compared
with KMT2D WT (WT-m1).
(legend continued on next page)




HDAC6, KMT2F, SETD4, KAT4, and KDM5B) whose loss can
significantly accelerate tumor growth. Interestingly we identified
four enzymes regulating H3K4 methylation, namely, KMT2D
(Herz et al., 2012), KDM5B (Seward et al., 2007), KMT2F (Wy-
socka et al., 2003), and KDM1A (Shi et al., 2004), as hits in this
screen, suggesting important roles for H3K4methylation reprog-
ramming during tumorigenesis. Similarly, KAT4 and HDAC6
suggest important roles for histone acetylation in melanomagen-
esis. Indeed, our previous study showed drastic deregulation of
chromatin states harboring H3K4 and histone acetylation during
pre-malignant to malignant transition in melanoma (Fiziev et al.,
2017). As the strongest phenotypes were observed for KMT2D,
we deeply studied its mechanism of action in melanoma.
Although the somatic loss-of-functionmutations in KMT2D are
observed across many malignancies (Cancer Genome Atlas
Network, 2015a; da Silva Almeida et al., 2015; Gao et al.,
2014; Grasso et al., 2012; Jones et al., 2012; Juhlin
et al., 2015; Kandoth et al., 2013; Lawrence et al., 2014; Lin
et al., 2014; Lohr et al., 2012; Morin et al., 2011; Parsons et al.,
2011; Pasqualucci et al., 2011; Pugh et al., 2012; Sausen et al.,
2015; Song et al., 2014), it is unclear why these mutations are
selected over the course of tumor evolution. Our study suggests
that enhancer reprogramming by KMT2D loss may rewire meta-
bolic pathways for increased energy and biomass needs of can-
cer cells. We observed drastic deregulation ofmultiplemetabolic
pathways in KMT2D mutant melanomas in both human and mu-
rine systems. Consistently, we observed a preferential depen-
dence of KMT2D mutant cells’ growth on glycolysis compared
with WT cells. The glycolysis pathway serves as a central node
for various needs of a proliferating cells (Lunt and Vander Heiden,
2011). It is required for a small fraction of energy needs (two
ATPs per cycle) and, more importantly, for the production of
biomass needed for cell doubling. For example, glucose-6-
phosphate provides a gateway to nucleotide biosynthesis and
dihydroxyacetone phosphate acts as a starting substrate for
the lipid biosynthesis pathway. Increased pyruvate production
due to high glycolysis provides a substrate for the OxPhos
pathway (to generate 36 ATPs), which is also upregulated in
the KMT2D mutant cells, thereby leading to enhanced ATP pro-
duction. Finally, 3-phosphoglycerate and other OxPhosmetabo-
lites provide a substrate for amino acid biosynthesis. Therefore,
upregulated glycolysis in KMT2D mutant cells contributes
to several different biomass and energy needs to enhance
tumorigenesis.
Data shown here along with our recent data in lung cancer
(Alam et al., 2020) show the dependence of KMT2D mutant can-
cers on glycolysis and, critically, will inform future clinical studies
testing potent glycolysis-blocking inhibitors in this genetic
context. Our data also suggest the potential use of IGF receptor
blocking molecules, such as linsitinib, which is being tested in
clinical trials (Iams and Lovly, 2015), in the KMT2Dmutant patient
population. However, further work may be needed to better
stratify the functional driver mutations in KMT2D because it is
likely to harbor higher mutations due to its excessive length
(42 kb). Therefore, some of the observed somatic mutations
may be passenger events, especially in cancers with a high mu-
tation burden, such as melanoma and lung cancers (Lawrence
et al., 2013). In addition to mutations, KMT2D expression levels
may also need consideration while stratifying patients for such
therapies, as many metastatic and primary melanomas show lit-
tle to no expression of KMT2D.
Although we show an important role for glycolysis, many other
metabolic pathways, such as oxidative phosphorylation and
fatty acid metabolism, are also highly upregulated in KMT2D
mutant cancers. The publicly available CRISPR screening plat-
form Achilles (Tsherniak et al., 2017) suggests a dependency
of KMT2D mutant melanomas on specific genes in these other
metabolic pathways that need further exploration. Indeed, a
recent study suggested enhanced fatty acid metabolism in
pancreatic cancer (Koutsioumpa et al., 2019). Although we
focused this study on metabolic reprogramming functions of
KMT2D, it is likely only one of the many factors contributing to
the growth of KMT2D-deficient cells and their selection. Future
studies will shed light on other aspects of KMT2D biology,
including its role in other pathways, such as immune
microenvironment.
KMT2D is a member of the COMPASS (complex of proteins
associated with set1) complex that is thought to be critical for
depositing H3K4me3 (Hu et al., 2013; Sze and Shilatifard,
2016). Furthermore, some studies, such as one by Dhar
et al. (2018) suggest a role of KMT2D in H3K4me3 regulation.
However, several other studies suggest KMT2D to be a major
(B) Western blot showing the expression of pAKT, AKT, pIGF1R, and IGF1R in KMT2Dmutant andWTmurine (left panel) and human (right panel) cells. Vinculin is
used as a loading control.
(C) Immunohistochemistry images for pAKT and pIGF1R demonstrating their overexpression in iBIP;KMT2D+/+ and iBIP;KMT2DL/L melanoma tumors. Scale bars
represent 20 mm.
(D) Boxplot showing RPPA-based protein levels of AKT, pAKT (S473), and pAKT (T308) in CCLE cell lines (all cancer types) that harbor KMT2D functional
mutations (n = 15) versus those that harbor WT and high levels of KMT2D (n = 15; RPKM R 10).
(E and F) Bar graph showing relative expression pattern of 12 glycolysis enzyme genes (compared to 28S) (n = 3 for each sample) in KMT2Dmutant andWTmurine
(E) and human (F) cells treated with vehicle or linsitinib (1 mM) for 24 h. t test, *p < 0.05, **p < 0.01. Data are presented as the mean ± SEM (error bars) of at least
three independent experiments or biological replicates.
(G) Growth curves for KMT2Dmutant andWTmurine (left) and human (right) melanoma cells treated with different concentrations of linsitinib. Relative confluence
at 96-h posttreatment are plotted, and IC50 values are shown in the accompanying table.
(H and I) Line plot showing average tumor volumes for mice (n = 5 per group) injected with KMT2D mutant and WT murine (H) and human (I) melanoma cells and
treated with linsitinib (25mg/kg) or vehicle (30% PEG-400) every other day. p values represent t test comparison between the indicated groups on the last time
point. In this graph, * p < 0.05, ** p < 0.01, *** p < 0.0001.
(J) Boxplot showing log(IC50) values for linsitinib in the KMT2Dmutant (n = 77) and KMT2DWT-high (n = 155) cell lines (all cancer types) from theGDCdata (Sanger
Cell Line Project).
In the boxplots (D) and (J), the bottom and the top rectangles indicate Q1 and Q3, respectively. The horizontal lines in the middle signify the Q2, and the vertical
lines that extend from the top and the bottom of the plot indicate the maximum and minimum values, respectively.
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regulator of the H3K4me1 mark that marks poised enhancers
(Cho et al., 2012; Dorighi et al., 2017; Herz et al., 2012; Hu
et al., 2013; Lee et al., 2013; Raman and Rai, 2018; Wang
et al., 2016). In a subset of enhancers, H3K4me1 recruits CBP/
p300 enzymes in turn activation their target genes (Lai et al.,
2017); however, a complete understanding of this mode of active
enhancer regulation is still lacking. Our data suggest that KMT2D
is a major regulator of H3K4me1 in melanoma. Because it ap-
pears that the extent of H3K4me1 loss is more than H3K27ac
loss at the global level, it is possible that in a subset of enhancers
other histone acetylations (than H3K27ac) may be involved in
enhancer activation in KMT2D mutant melanomas. Indeed, evi-
dence for roles of the other histone acetylations in enhancer acti-
vation has been previously demonstrated (Pradeepa et al.,
2016). Our previous study also showed drastic losses of chro-
matin states harboring multiple different histone acetylations,
including H2BK5ac and H4K5ac, and H3K4me1/2/3 in early
stages of tumorigenic transition in melanoma (Fiziev et al.,
2017). Nonetheless, the ChIP-seq data for active enhancers,
for which we probe the co-occupancy of H3K27ac and
H3K4me1, clearly suggest that many active enhancers are lost
in KMT2D-deficient cells in the murine system (Figure 5H).
Indeed, locus-specific changes in chromatin states are the de-
terminants of expression of a specific gene. Because enhancers
are shown to be cell type specific (Kundaje et al., 2015), KMT2D-
loss-mediated enhancer misregulation could be responsible for
different downstream mechanisms upon KMT2D deficiency in
different cancer types (such as Per2 in lung cancer, IGFBP5 in
melanoma, or SLC2A3 and TSC1 in pancreatic cancer) (Kout-
sioumpa et al., 2019).
We noted that KMT2Dmutant cells grew slower thanWT cells
in vitro; however, they proliferated faster in vivo and formed
aggressive tumors. There may be several reasons for why
KMT2D mutant cells did not grow faster than WT cells in vitro;
however, they formed aggressive tumors in vivo. First, due to
the rapid consumption of glucose because of their faster meta-
bolism (Figures S4A and S4B), KMT2D mutant cells likely slow
once nutrients are exhausted from the media. Indeed, the
establishment of KMT2D mutant cells from GEMM
(iBIP;KMT2DL/L) tumors required a repeated change of DMEM
media with high glucose every 3–4 h (Figures S4A and S4B).
Second, other factors in the tumor microenvironment (which
are lacking in the in vitro culture conditions) may play important
roles in supporting the growth of KMT2D mutant cells. Indeed,
pathway analysis of the differential gene expression data
suggests that idea as well. We noted immune pathways to be
enriched in KMT2D-deficient tumors. Other events, such as
hypoxia, that occur more prominently under in vivo conditions,
may also play important roles in promoting the growth of
KMT2D mutant cells. Indeed, HIF1a expression was modestly
higher (1.5- to 2-fold) in KMT2D mutant cells compared with
WT cells. Third, it is possible that KMT2D loss promotes the
fitness of slow cycling cells in vitro and that these fitter cells
rapidly proliferate once they encounter an optimal environment
(i.e., tumormicroenvironment) in vivo. Indeed, the evidence for a
role for KMT2D in clonal fitness in the hepatic disease was
recently shown (Zhu et al., 2019).
Overall, our study provides evidence for the dependency of
the KMT2D mutant melanomas on glycolysis and the IGF
pathway by enhancer reprogramming. These results suggest a
potential therapeutic strategy in the patients with melanoma
harboring mutations in this epigenetic regulator.
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Figure 7. Loss of Distal Enhancers of IGFBP5 in KMT2D Mutant Cells Partially Contributes to Its Phenotypes
(A) IGV snapshot showing RNA-seq, H3K27Ac, and H3K4me1 ChIP-seq signal tracks for genomic locus harboring IGFBP5. Note the loss of blue peaks in the
region surrounding the IGFBP5 gene.
(B) Interaction map frommouse embryonic stem cells (ESCs) showing an IGFBP5-containing locus, demonstrating an interaction between the IGFBP5 gene with
proximal and distal enhancers. The highlighted blue off-diagonal interaction (box with arrow) points to a downstream enhancer that exhibits a selective loss of
H3K4me1 signal in KMT2D mutant samples.
(C) Western blot showing expression of IGFBP5 and vinculin in KMT2D mutant and WT murine (top panel) and human (bottom panel) cells.
(D) Boxplot showing expression of IGFBP5 in the melanoma TCGA samples that harbor functional mutations (nonsense, frameshift or post4700aa) (n = 15) or WT
copies for KMT2D (n = 15, RPKM > 10). The bottom and the top rectangles indicate Q1 and Q3, respectively. The horizontal lines in the middle signify Q2, and the
vertical lines that extend from the top and the bottom of the plot indicate the maximum and minimum values, respectively. * denotes p <0.05.
(E) western blot showing expression of IGFBP5, pAKT, AKT, pIGF1R, and IGF1R in KMT2D mutant and WT murine control or IGFBP5 overexpressing cells.
Vinculin is used as a loading control.
(F and G) Bar graph showing relative expression pattern of 12 glycolysis enzyme genes (compared to 28S) (n = 3 for each sample) in KMT2D mutant and WT
murine (F) and human (G) cells overexpressing empty vector or IGFBP5. Standard t test, *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as themean ± SEM
(error bars) of at least three independent experiments or biological replicates.
(H)Model ofmolecular mechanism of KMT2D-loss-mediated promotion of humanmelanoma.We suggest that KMT2D loss reprograms a subset of enhancers for
important regulators of tumor suppressor pathways, including IGFBP5 (and others denoted by TS prefix). Lower levels of IGFBP5 upon KMT2D loss amplifies IGF
signaling, thus activating AKT-mediated metabolic reprogramming, including activation of glycolysis.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
H3K4me1 Abcam Cat# ab8895; RRID: AB_306847
H3K27Ac Abcam Cat# ab4729; RRID: AB_2118291
H3K4me3 Abcam Cat# ab8580; RRID: AB_306649
H3K27me3 Abcam Cat# ab6002; RRID: AB_305237
H3K79me2 Abcam Cat# ab3594; RRID: AB_303937
H3 Abcam Cat# ab1791; RRID: AB_302613
KMT2D Sigma Cat# HPA035977, RRID: AB_10670673
IGFBP5 Proteintech Cat# 55205-1-AP; RRID: AB_2736835
Ki-67 Cell Signaling Technology Cat# 9027; RRID: AB_2636984
ENO1 Proteintech Cat# 11204-1-AP; RRID: AB_2099064
PGK1 Proteintech Cat# 17811-1-AP; RRID: AB_2161218
PGAM1 Proteintech Cat# 16126-1-AP; RRID: AB_2160786
AKT Cell Signaling Technology Cat# 4691; RRID: AB_915783
pAKT Cell Signaling Technology Cat# 9271; RRID: AB_329825
IGF1R Cell signaling Technology Cat# 9750; RRID: AB_10950969
pIGF1R Abcam Cat# ab39398; RRID: AB_731544
Vinculin Sigma-Aldrich Cat# V4139, RRID: AB_262053
Tyrosinase Abcam Cat# ab738; RRID: AB_305899
Rabbit-on-Rodent HRP-Polymer Biocare Medical Cat# RMR622L
Mouse-on-Mouse HRP-Polymer Biocare Medical Cat# MM510L
Alexa 488-conjugated anti-mouse IgG Life technologies Cat# A-11029; RRID: AB_138404
Alexa 488-conjugated anti-rabbit IgG Life technologies Cat# A-11037; RRID: AB_2534095
Chemicals, Peptides, and Recombinant Proteins
2-Deoxy-D-glucose (2-DG) Sigma Cat# D6134; CAS: 154-17-6
Linsitinib Selleck Chemicals Cat# HY-10191; CAS: 867160-71-2
Lonidamine Sigma Cat# L4900; CAS: 50264-69-2
POMHEX Gift from Dr. Florian Muller
(Lin et al., 2018)
N/A
IACS-010759 Gift from Dr. Joseph R. Marszalek N/A
Deposited Data
ChIP-seq and RNA-seq for iBIP;KMT2D+/+
and iBIP;KMT2DL/L melanoma tumors
This paper GEO: GSE 116921
Experimental Models: Cell Lines
Human: HMEL-BRAFV600E Gift from Dr. David Fisher’s
laboratory
N/A
Human: A375 ATCC CRL-1619
Human: RPMI-7951 ATCC HTB-66
Human: WM115 ATCC CRL-1675
Human: WM266-4 ATCC CRL-1676
Human: SKMEL-24 ATCC HTB-71
Human: WM278 ATCC CRL-2809
Mouse: 5770 This paper N/A
Mouse: 300 This paper N/A
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse: 3417 This paper N/A
Mouse: 3418 This paper N/A
Experimental Models: Organisms/Strains
Mouse: Kmt2dfl/fl (also called Mll4fl/fl) Dhar et al., 2018 N/A
inducible BRAF INK/ARF PTEN (iBIP) mice Kwong et al., 2015 N/A
Xenograft Experiments (Swiss Nude) Experimental Radiation
Oncology at MDACC
Nude
Xenograft Experiments (NCr Nude) Taconic Biosciences NCRNU-F
Oligonucleotides
Primers for quantitative RT-PCR
(human and mouse): See Table S4
N/A N/A
Recombinant DNA
pInducer20-KMT2D This study N/A
shKmt2d-01 (mouse) Sigma-Aldrich Cat# TRCN0000239234
shKmt2d-03 (mouse) Sigma-Aldrich Cat# TRCN0000239233
Software and Algorithms
cBio cancer genomics portal Gao et al., 2013 http://www.cbioportal.org/
Pyflow-ChIPseq Terranova et al., 2018 https://github.com/crazyhottommy/
pyflow-ChIPseq
Bowtie1 Langmead et al., 2009 http://bowtie-bio.sourceforge.net/
index.shtml
samtools Li et al., 2009 http://www.htslib.org/
Deeptools Ramı́rez et al., 2016 https://deeptools.readthedocs.io/en/develop/
MACS14 Zhang et al., 2008 https://github.com/macs3-project/MACS
ROSE Lovén et al., 2013 http://younglab.wi.mit.edu/super_enhancer_
code.html
chromHMM Ernst and Kellis, 2012 http://compbio.mit.edu/ChromHMM/
EnrichedHeatmap Gu et al., 2018 https://bioconductor.org/packages/release/
bioc/html/EnrichedHeatmap.html
ComplexHeatmap Gu et al., 2016 https://bioconductor.org/packages/release/
bioc/html/ComplexHeatmap.html
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
featureCounts Liao et al., 2014 http://subread.sourceforge.net/
ChIPseeker Yu et al., 2015 https://bioconductor.org/packages/release/
bioc/html/ChIPseeker.html
DESeq2 Love et al., 2014 http://bioconductor.org/packages/release/
bioc/html/DESeq2.html
TCGAbiolinks Colaprico et al., 2016 https://bioconductor.org/packages/release/
bioc/html/TCGAbiolinks.html
GSEA Subramanian et al., 2005 https://www.gsea-msigdb.org/gsea/
Snakemake Köster and Rahmann, 2012 https://snakemake.readthedocs.io/en/stable/
Pyflow-RNaseq This paper https://github.com/crazyhottommy/pyflow-
RNaseq
IGV Robinson et al., 2011 https://software.broadinstitute.org/software/igv/
ggplot2 Wickham, 2006 https://ggplot2.tidyverse.org/
MetaboAnalyst 2.0 Xia et al., 2012 https://www.metaboanalyst.ca
GraphPad Prism https://www.graphpad.com/scientific-software/
prism/






Requests for further information and reagents should be directed to and will be fulfilled by the Lead Contact, Kunal Rai (krai@
mdanderson.org).
Materials availability
Any plasmid and cell line generated in this study are available from the Lead Contact with a completedMaterials Transfer Agreement.
Data and code availabilty
The accession number for the RNA-Seq and ChIP-Seq data reported in this paper is GEO: GSE116921. All codes are available at
https://gitlab.com/railab.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
All melanoma cell lines (HMEL-BRAFV600E, A375, RPMI-7951, WM115, SKMEL-24, WM278, 5770, 300, 3417 and 3418) that were
used in this study are described in the Key Resources Table, and they were cultured within 10 to 15 passages. Cell culture reagents
and other chemicals were purchased from Thermo Fisher Scientific (GIBCO & Hyclone), Sigma-Aldrich, and Fisher Bioreagents.
Mouse strains and genetically engineered mouse models (GEMM)
All animal studies were performed according to University of Texas MD Anderson Cancer Center Institutional Animal Care and Use
Committee (IACUC) approved protocols.
GEMM model
The KMT2Dfl/fl mice were previously described (Dhar et al., 2018). KMT2Dfl/fl mutant mice were crossed with iBIP mice (Kwong et al.,
2015) (iBIP = Tyr-CreERT2, Rosa26-rtta, TetO-BRAFV600E, PTENL/L, INK/ARFL/L; mixed genetic background of FVB and B6) to
generate iBIP;KMT2DL/+ genotype containing mice. The iBIP;KMT2DL/+ male and female mice were mated to generate
iBIP;KMT2D+/+, iBIP;KMT2DL/+, and iBIP;KMT2DL/L genotype containing cohorts. Genotypes of these mice were confirmed by a
standard PCR-based protocol. The primers used for the genotyping are listed in Table S4. In this model, upon weaning and cohort
generation (4–6 weeks old), mice were fed with doxycycline (2mg/ml in 40mg/ml of water, ad libitum) and 4-OHT (1 mM) was applied
on the ears at weaning age to generate auricular tumors. Both female and male mice were used in approximately similar numbers.
The tumor progression and survival of mouse groups were compared. Tumors were harvested by excision of the lesion and digested
for generation of WT-m1, WT-m2, Mut-m1 and Mut-m2 cell lines. For chromatin immunoprecipitation (ChIP) and RNA analyses, the
distinct tumors were dissected, washed with ice-cold phosphate-buffered saline solution (PBS) and snap frozen.
Xenograft experiments
For the xenograft experiments (as described below) in the RNAi screen and subsequent validations, we used NCr Nude mice from
Taconic. For all inhibitor treatment experiments, we used the Swiss Nude mice. Four to six weeks old females were used to avoid
fighting wounds.
Study approval
The care and use of all mice were approved by the Institutional Animal Care and Use Committee (IACUC) of The University of Texas
MD Anderson Cancer Center.
METHOD DETAILS
Cell culture, stable cell generation and inhibitor treatment
HMEL-BRAFV600E, A375, RPMI-7951, WM115 and WM266-4 cells were maintained in standard tissue-culture conditions in DMEM
media (high glucose) with 10% FBS. SKMEL-24 (Mut-h1) and WM278 (Mut-h2) cells were maintained in the recommended media,
except all assays were performed in the same media as for A735 (WT-h1) and RPMI-7951 (WT-h2). Mouse tumor cell lines 300 (WT-
m1), 5770 (WT-m2), 3417 (mut-m1) and 3418 (Mut-m2) were isolated from melanoma tumors by digestion in RPMI media (Sigma)
using collagenase (2mg/ml) (GIBCO) and dispase (4mg/ml) (GIBCO). Single cell suspension was generated using MACS homogeniz-
er (Milteny Biotec) followingmanufacturer’s mTumor protocol. Cells were plated in DMEMwith high glucose (Sigma/GIBCO) andGlu-
tamax (Sigma/GIBCO) and replenished every 4 h. Once cultures were stable, cells were maintained in DMEM with high glucose and
Glutamax. Stable lines expressing shRNAs and ORFs were established by standard lentiviral mediated transduction. All cells were
routinely tested for mycoplasma by mycoAlert kit (Lonza) or by PCR.





For inhibitor treatment experiments, cells were seeded in 96-well plates at a density of 500 cells per well and treated 24-hours later
with specific inhibitors. Linsitinib (SelleckChem), 2-Deoxy-D-Glucose (2-DG, Sigma) and Lonidamine (Sigma) were dissolved in
DMSO and diluted in cell culture media for treatment. Cell density was measured by imaging every 3–4 h using an IncuCyte live
cell analysis system (Essen Bioscience). Once treated cells reached confluence (90%–100%), they were stained with crystal violet
and destained in 10% acetic acid. Absorbance was read at 590nM and background-corrected readings for each condition were
normalized to vehicle treatments which were plotted to obtain the growth curves. IC50 values were calculated using GraphPad Prism.
RNAi screen
For the screen, 475 shRNAs against 95 chromatin modifiers (Table S1) in pLKO.1 vector were obtained from the Broad Institute/Har-
vard Medical School core facility. Lentiviruses were produced in HEK293T cells in a 6-well format using pDelta8.2 and pMD2.G
(addgene). Viruses for 25 shRNAs (five shRNAs for each of five genes selected at random) were pooled together and the mixture
was used to transfect onemillion cells at MOI of 1. Cells were grown for 3 days and subsequently grafted intradermally into the flanks
of NCR-NUDE mice at a density of 1million per flank. All mice experiments were performed per Institutional Animal Care and Use
Committee (IACUC) guidelines. Mice were monitored weekly for tumor growth and sacrificed when tumor size reached 2 cm in
one dimension. At sacrifice, tumors were harvested and genomic DNA prepared. The segment of pLKO.1 containing shRNA
sequence was amplified by PCR and then sequenced to identify the integrated shRNA. Genes corresponding to these shRNAs
were noted as hits from the primary screen. We did not observe two different shRNAs for any gen hit. Only one shRNA hit per
genewas identified. For validation experiments, stable HMEL-BRAFV600E cells were generated using individual shRNAs, withmultiple
shRNAs targeting each gene from primary hits. Cell lines generated from the two best shRNAs demonstrating the best knockdown of
the corresponding gene (and with at least 50% knockdown) were then injected intradermally in the flanks of NCR-NUDE mice (one
million cells/injection). Mice were monitored for tumor formation and growth.
Mouse experiments
All mice were kept in specific pathogen free vivarium at the MD Anderson Cancer Center mouse facilities. Mice were fed commercial
rodent diet (PicoLab Rodent diet 5053 from Labdiet) and water ad libitum.
Xenograft experiments
Mice were injected with five million cells in one flank each andmonitored every other day for tumor growth. When tumor size reached
0.5 cm in one mouse in each treatment arm, all mice were injected with 2-DG (500mg/kg dissolved in PBS) or Linsitinib (25mg/kg
dissolved in 30% PEG-400) via intraperitoneal route. Tumor volume was measured every other day.
Genetically engineered mouse model
KMT2D conditional mutant mice were obtained from Dr. MinGyu Lee (Dhar et al., 2018). These mice are engineered with Lox sites
flanking exons 16 and 20, resulting in loss of KMT2D protein as previously described (Dhar et al., 2018). KMT2D mutant mice were
crossed with iBIP mice (Kwong et al., 2015) (iBIP = Tyr-CreERT2, Rosa26-rtta, TetO-BRAFV600E, PTENL/L, INK/ARFL/L; mixed genetic
background of FVB and B6) to generate iBIP;KMT2DL/+ genotype containing mice (as assessed by genotyping for all alleles). The
iBIP;KMT2DL/+male and femalemiceweremated to generate iBIP;KMT2D+/+, iBIP;KMT2DL/+, and iBIP;KMT2DL/L genotype contain-
ing cohorts. These mice were treated with doxycycline systemically (2mg/ml in 40mg/ml of water) by feeding (ad libitum) and 4-OHT
(1 mM) was applied on the ears to generate auricular tumors. Mice were observed twice a week for tumor formation and upon tumor
appearance, tumor growth was measured every other day. Tumors were harvested by excision of the lesion and digested for gen-
eration of WT-m1, WT-m2, Mut-m1 and Mut-m2 cell lines.
RNA-Seq analysis of murine tumor cells
Strand specific libraries were constructed using the ScriptSeq Kit (Epicenter/Illumina). RNaseq data were processed by pyflow-RNa-
seq (Tang, 2017b), a snakemake based RNaseq pipeline. Raw reads were mapped by STAR (Dobin et al., 2013), RPKM normalized
bigwigs were generated by deeptools (Ramı́rez et al., 2016), and gene counts were obtained by featureCount (Liao et al., 2014). Dif-
ferential expression analysis was carried out using DESeq2 (Love et al., 2014). Gene set enrichment analysis (GSEA) was done using
the GSEA tool (Subramanian et al., 2005) from Broad Institute. The pre-rank mode was used. The signed fold change *–log10(pvalue)
metric was used to pre-rank the genes.
ChIP-Seq
Chromatin immunoprecipitation was performed as described earlier (Terranova et al., 2018) with optimized shearing conditions and
minor modifications for melanocytes. The antibodies used were: H3K4me1 (Abcam ab8895), H3K27ac (Abcam ab4729), H3K4me3
(Abcam ab8580), H3K79me2 (Abcam ab3594), H3K27me3 (Abcam ab6002). ChIP-seq data were quality controlled and processed
by pyflow-ChIPseq (Tang, 2017a), a snakemake (Köster and Rahmann, 2012) based ChIPseq pipeline. Briefly, raw reads were map-
ped by bowtie1(Langmead et al., 2009) to hg19. Duplicated reads were removed and only uniquely mapped reads were retained.
RPKM normalized bigwigs were generated by deep tools (Ramı́rez et al., 2016) and tracks were visualized with IGV (Robinson




et al., 2011). Peaks were called using macs1.4 (Zhang et al., 2008) with a p value of 1e-9. Chromatin state was called using
ChromHMM (Ernst and Kellis, 2012) and the emission profile was plotted by ComplexHeatmap (Gu et al., 2016). Heatmaps were
generated using R package EnrichedHeatmap (Gu et al., 2018). ChIP-seq peaks were annotated with the nearest genes using
ChIPseeker (Yu et al., 2015). Super-enhancers were identified using ROSE (Lovén et al., 2013) based on H3K27ac ChIP-seq data.
Chromatin state analysis
ChromHMM (Ernst and Kellis, 2012) was usedwith default parameters to derive genome-wide chromatin statemaps for all cell types.
Input data were binarized using ChromHMM’s BinarizeBed method (Ernst and Kellis, 2012) with a p value cutoff of 1e-4. Chromatin
state models were learnt jointly on all data for all five histone marks (H3K4me1, H3K4me3, H3K27ac, H3K79me2 and H3K27me3)
from WT-m1 and Mut-m2 tumor cells and a model with 10 states was chosen for detailed analysis. Chromatin state segmentations
of WT-m1 andMut-m212 were produced subsequently by applying this model to the original binarized, quantile normalized or down-
sampled chromatin data from these cell types.
TCGA RNA-Seq data analysis
TCGAmelanoma (SKCM) RNaseq raw counts were downloaded using TCGAbiolinks (Colaprico et al., 2016). The mutation MAF files
were downloaded with TCGAbiolinks as well. Mutation status of KMT2D was inferred from the MAF files. Ten SKCM primary tumor
samples with wild-type copies of KMT2D and expressing high levels and 10 SKCM primary tumor samples with mutant KMT2D (see
supplemental data for samples included in the analysis) were compared using DESeq2, the signed fold change *–log10(pvalue)
metric was used to pre-rank the gene list and for GSEA pre-rank analysis. Boxplots were generated using R package ggplot2 (Wick-
ham, 2006).
For the pan cancer analysis, TCGA tumor samples were grouped based on KMT2D gene expression and mutation status: KMT2D
mutation free group are samples with high KMT2D expression (among the top quantile) and no somatic mutation; KMT2D mutated
group are samples with low KMT2D expression (falling into the bottom quantile) and have either nonsense mutations or missense
mutations with the amino acid 4,700. Six tumor types (BLCA, urothelial bladder carcinoma; CESC, cervical squamous cell carcinoma
and endocervical adenocarcinoma; HNSC, head and neck squamous cell carcinoma; LUSC, lung squamous cell carcinoma; UCEC,
uterine corpus endometrial carcinoma; STAD, stomach adenocarcinoma) had adequate sample size (R10) to be included for differ-
ential gene expression analysis and pathway enrichment analysis. TCGA normalized RNaseq read count were processed by Wil-
coxon test to identify differentially expressed genes (DEGs) across KMT2D mutation status groups. A cut-off of gene expression
fold change ofR 2 or% 0.5 and a FDR q-value of < 0.05 were applied to select the most differentially expressed genes. A ranked
list of genes was generated based on the product of Wilcoxon test FDR q-values and log2 fold change for all coding genes and pro-
cessed by Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) against the curated gene sets fromMolecular Signature
Database (MSigDB) (Liberzon et al., 2015) to identify significantly enriched signaling pathways.
Immunohistochemistry
Tumors were fixed in formalin for 24 h, paraffin embedded, sectioned, and stained according to standard procedures. Briefly, endog-
enous peroxidases were inactivated by 3% hydrogen 673 peroxide. Non-specific signals were blocked using 3% BSA, 10% goat
serum in 0.1% Triton X-100. After antigen retrieval in citrate buffer, slides were stained using respective antibodies overnight at
4C, [ ENO1 (Proteintech, #11204-1-AP), PGK1 (Proteintech #17811-1-AP), PGAM1 (Proteintech, #16126-1-AP), Tyrosinase (Abcam,
ab738), pAKT (Cell Signaling, #9271), pIGF1R (Abcam, ab39398)]. After overnight incubation, the slides were washed and incubated
with secondary antibody (HRP-polymers, Biocare Medical) for 30 min at room temperature. The slides were washed three times and
stained with DAB substrate (ThermoFisher Scientific). The slides were then counterstained with hematoxylin and mounted with
mounting medium.
Inducible ectopic expression of KMT2D
Full-length KMT2D was cloned from KMT2D overexpression vector (gift from Dr. Laura Pasqualucci at Columbia University) into the
pInducer20 doxycycline inducible lentiviral vector (Addgene 44012). Lentivirus was produced using standard virus production
methods by co-transfecting target and packaging plasmids (psPAX2 – Addgene12260 and pMD2.G- Addgene 12259) into
HEK293T cells. Cell lines were then transduced with 0.45uM filtered and ultracentrifuge concentrated viral particles with Polybrene
(8 mg/ml). After 16 h of transduction, media was changed into fresh regular growth media, and 48 h later selection started using G418
(0.2-0.6mg/ml). After selection was complete in 120 h, cells were termed stably transduced. KMT2D expression was induced for 72 h
with doxycycline 2 mg/ml.
Whole Cell Extracts, Acid Extraction and Western Blotting
Cells were harvested in media, washed with PBS, and pelleted. Cell pellets were dissolved in RIPA buffer (25mM Tris PH8, 150mM
NaCl, 01% SDS, 0.5% Sodium Deoxycholate, 1% Triton X-100, Protease and phosphatase inhibitor cocktail; bought from Boston
bioproducts) and incubated for 30’ on ice before brief sonication followed by centrifugation to remove debris. Supernatant was
collected, protein measured using Bradford assay and equal amounts were loaded on the 4%–12%SDS-PAGE gel (Invitrogen). Pro-
teins were transferred to a Nitrocellulose or PVDF membrane which was then blocked in Odyssey Blocking buffer (LiCOR) and




incubated with primary antibody overnight in the same buffer. Blots were then washed and probed with HRP-labeled secondary an-
tibodies (Pierce) and developed using a X-ray film (Phenix). For histone marks, we incubated cell pellets in Triton Extraction buffer
(PBS containing 0.5% Triton X-100 (v/v), 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN3) for nuclei isolation. Nuclei
were subjected to histone extraction by overnight incubation in 0.2N HCl (with protease and phosphatase inhibitors) followed by
centrifugation. Rest of the western blotting was done as explained above. Antibodies used were (also listed in Key Resources Table):
IGFBP5 (Proteintech, #55205-1-AP), pAKT (Cell Signaling, 9271) Total AKT (CST, #4691), Total IGF-1R (Cell signaling, #9750). His-
tone antibodies are same as used for ChIP experiments.
Metabolomics via selected reaction monitoring tandem mass spectrometry
One 15 cm2 plate of cells (10–15 million) per sample was extracted with 80%methanol (80C) for 15 min. Dried metabolite pellets
were resuspended in 20 mL of LC/MS-grade water, and 5 mL aliquots were injected for targeted LC/MS/MS on a 5500 QTRAP hybrid
triple-quadrupole mass spectrometer coupled to a Prominence ultrafast liquid chromatography (UFLC) system from 287 selected
reaction monitoring (SRM) transitions with positive/negative polarity switching. Samples were separated on a 4.6 mm i.d. 3
100 mm Amide XBridge hydrophilic interaction liquid chromatography (HILIC) column at 360 mL/min starting from 85% buffer B
(100% ACN) and moving to 0% B over 16 min. Buffer A was 20 mM NH4OH/20 mM CH3COONH4 (pH = 9.0) in 95:5 water/ACN.
Q3 peak areas were integrated by use of MultiQuant 2.1 software (AB/SCIEX). MetaboAnalyst 2.0 (Xia et al., 2012; https://www.
metaboanalyst.ca) was used to normalize data. All metabolite samples were prepared as biological triplicates.
RT-qPCR
RNA was isolated using RNeasy kit (qiagen) or Trizol (Thermo Fisher) reagent using manufacturer’s protocol. cDNA was prepared
using SuperScript III first strand synthesis kit (Thermo Fisher) using 2micrograms of RNA and manufacturer’s protocol. Quantitative
PCR was performed using QuantiTect Sybr Green PCR kit in Stratagene’s Mx3000p system. Primers used are listed in Table S4.
Tissue microarray
The tissue microarray containing 100 samples (62 cases of primary melanoma, 22 cases of metastatic melanoma, and 18 nevi) was
obtained from US Biomax. The staining for KMT2D antibody (Sigma, Prestige) was performed at the immunohistochemistry core at
MD Anderson Cancer Center. Two pathologists read the TMA and consensus scores were assigned to each sample. For the histone
modification study, we built and stained a TCGA melanoma tumor TMA of 65 samples. TMA was stained with KMT2D (Sigma),
H3K4me1 (Abcam ab8895), H3K27ac (Abcam ab4729), H3K4me3 (Abcam ab8580), antibodies. Each sample was represented in
two cores and intensity data were averaged between the two cores.
Mass spectrometry analysis of histone modifications (Mod-Spec)
Histones were acid extracted, derivatized via propionylation, digested with trypsin, newly formed N-termini were propionylated as
previously described (Garcia et al., 2007) and then measured three separate times using the Thermo Scientific TSQ Quantum Ultra
mass spectrometer coupled with an UltiMate 3000 Dionex nano-liquid chromatography system. The data were quantified using
Skyline (MacLean et al., 2010) and represents the percent of each modification within the total pool of that amino acid residue.
QUANTIFICATION AND STATISTICAL ANALYSIS
The two-tailed Student’s t test was used to determine the statistical significance of two groups of data using GraphPad Prism. Data
are presented as means ± standard error of the mean (SEM; error bars) of at least three independent experiments or three biological
replicates. p values of less than 0.05 were considered statistically significant.
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